{
    "key_points": [
        "Pfizer Inc. announced it is seeking Emergency Use Authorization (EUA) for its oral antiviral candidate, PAXLOVIDâ„¢, for treatment of COVID-19 in high-risk patients.",
        "PAXLOVID could be the first oral antiviral 3CL protease inhibitor specifically designed to combat SARS-CoV-2.",
        "Clinical data shows an 89% reduction in risk of COVID-19-related hospitalization or death compared to placebo within three days of symptom onset.",
        "Rolling submissions for PAXLOVID have commenced in several countries, including the United Kingdom, Australia, New Zealand, and South Korea.",
        "Pfizer is investing up to $1 billion of its own funds for the manufacturing and distribution of PAXLOVID.",
        "Pfizer has signed a voluntary licensing agreement with the Medicines Patent Pool (MPP) to expand access in 95 low- and middle-income countries.",
        "PAXLOVID is to be prescribed at the first sign of infection or awareness of exposure to potentially avoid severe illness.",
        "Investigational treatment will be administered as a dose of 300mg of PF-07321332 with one 100mg tablet of ritonavir, taken twice-daily for five days.",
        "Pfizer will offer investigational oral antiviral therapy through a tiered pricing approach based on each country's income level.",
        "The Phase 2/3 EPIC-HR study interim analysis evaluated data from 1,219 adults, demonstrating significant reduction in COVID-19-related hospitalization or death."
    ],
    "spokespersons": [
        "Albert Bourla (Chairman and Chief Executive Officer, Pfizer)"
    ],
    "article_type": "press release",
    "dateline": "NEW YORK",
    "audience": "general public",
    "stance": "neutral"
}